Biora Therapeutics Valuation

Is 4ZU0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4ZU0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 4ZU0's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 4ZU0's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4ZU0?

Key metric: As 4ZU0 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 4ZU0. This is calculated by dividing 4ZU0's market cap by their current revenue.
What is 4ZU0's PS Ratio?
PS Ratio8x
SalesUS$892.00k
Market CapUS$7.10m

Price to Sales Ratio vs Peers

How does 4ZU0's PS Ratio compare to its peers?

The above table shows the PS ratio for 4ZU0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3x
CNW co.don
0.7xn/a€6.5m
MDG1 Medigene
2.3x13.3%€17.4m
BPXA Bellicum Pharmaceuticals
0.5xn/a€772.4k
ECX Epigenomics
8.6xn/a€1.2m
4ZU0 Biora Therapeutics
8x60.3%€7.1m

Price-To-Sales vs Peers: 4ZU0 is expensive based on its Price-To-Sales Ratio (8x) compared to the peer average (3.8x).


Price to Sales Ratio vs Industry

How does 4ZU0's PS Ratio compare vs other companies in the DE Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIO3 Biotest
1.5x3.6%US$1.43b
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
4ZU0 8.0xIndustry Avg. 8.0xNo. of Companies7PS0612182430+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 4ZU0 is good value based on its Price-To-Sales Ratio (8x) compared to the European Biotechs industry average (8x).


Price to Sales Ratio vs Fair Ratio

What is 4ZU0's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4ZU0 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 4ZU0's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies